Related Experiment Videos
An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and
M C Benson1, D J McMahon, W H Cooner
1Department of Urology, Columbia University College of Physicians and Surgeons, J. Bentley Squier Urologic Clinic, Columbia-Presbyterian Medical Center New York, New York.
World Journal of Urology
|January 1, 1993
Summary
Prostate-specific antigen density (PSAD) improves prostate cancer detection over PSA alone, especially for intermediate PSA levels. Incorporating prostate volume with PSA is crucial for differentiating benign conditions from cancer.
Area of Science:
- Urology
- Oncology
- Diagnostic Imaging
Background:
- Prostate-specific antigen (PSA) is a key serum marker for prostate cancer (CaP).
- PSA sensitivity and specificity are limited, particularly for PSA values between 4.1-10.0 ng/ml, due to coexisting benign prostatic hyperplasia (BPH).
Purpose of the Study:
- To evaluate the utility of PSA density (PSAD), calculated as PSA divided by prostate volume, in differentiating CaP from BPH.
- To determine the clinical significance of PSAD across different serum PSA ranges.
Main Methods:
- Analysis of 3140 patients evaluated for prostate conditions.
- Stratification based on serum PSA, digital rectal examination (DRE), transrectal ultrasound (TRUS), and TRUS-determined prostate volume.
- Calculation and comparison of PSA and PSAD values.
Main Results:
- For PSA ≤ 4.0 ng/ml, neither PSA nor PSAD showed clinical significance in differentiating BPH from CaP.
- For PSA levels of 4.1-10.0 ng/ml, PSA was unable to differentiate BPH from CaP, while PSAD demonstrated statistical and clinical significance.
- For PSA levels of 10.1-20.0 ng/ml, only PSAD remained statistically significant.
Conclusions:
- Prostate biopsy is recommended for all patients with abnormal DRE or TRUS findings.
- For intermediate PSA levels (4.1-10.0 ng/ml), TRUS, prostate volume, and PSAD are essential for accurate diagnosis.
- PSAD is a valuable tool for improving diagnostic accuracy in specific PSA ranges, reducing unnecessary biopsies.